PARP抑制剂在实体瘤中的系统综述与荟萃分析
主要终点无进展生存期显著改善(HR 0.59,95%CI 0.51-0.68,p<0.001),且不受BRCA突变状态影响(p=0.65)。总缓解率和总生存期也显著改善,探索性分析显示BRCA野生型/HRR缺陷肿瘤中PFS亦显著改善(HR 0.51,95%CI 0.43-0.60,p<0.001)。
要点
- PARP抑制剂显著改善转移性实体瘤患者PFS(HR 0.59,95%CI 0.51-0.68)。
- PFS获益不受BRCA突变状态影响(交互p=0.65)。
- BRCA野生型/HRR缺陷肿瘤中PFS亦显著改善(HR 0.51,95%CI 0.43-0.60)。
核心结论
- 结果证实已获批PARP抑制剂方案在BRCA1/2突变实体瘤中的疗效,并支持其在BRCA非依赖的HRR缺陷肿瘤中的作用。
- 探索性分析提示PARP抑制剂在一些野生型肿瘤中可能具有更广泛疗效,或需合适的治疗搭档。
- 需要前瞻性研究进一步验证。
研究设计与样本
- 主要终点为无进展生存期(PFS),次要终点为总缓解率(ORR)和总生存期(OS)。
- 采用随机效应模型。
主要发现
- PFS显著改善(HR 0.59,95%CI 0.51-0.68,p<0.001),不受BRCA突变状态影响(p=0.65)。
- PFS亚组差异显著:肿瘤部位(p=0.001)、治疗线数(p=0.002)、对照臂(p<0.001)、PARP抑制剂类型(p<0.001)、试验分期(p=0.006)。
- ORR显著改善(相对风险1.35,95%CI 1.16-1.56,p<0.001),亚组差异见于治疗线数(p=0.03)、对照臂(p=0.04)、PARP抑制剂类型(p<0.001),与突变状态(p=0.44)、肿瘤部位(p=0.86)、试验分期(p=0.09)无关。
- OS显著改善(HR 0.86,95%CI 0.80-0.92,p<0.001),与突变状态(p=0.57)、肿瘤部位(p=0.82)、治疗线数(p=0.22)、对照臂(p=0.21)、PARP抑制剂类型(p=0.30)、试验分期(p=0.26)无关。
- 探索性亚组分析显示BRCA野生型/HRR缺陷肿瘤中PFS显著改善(HR 0.51,95%CI 0.43-0.60,p<0.001)。
临床怎么用
- 支持已获批PARP抑制剂方案用于BRCA1/2突变转移性实体瘤。
- 可考虑在BRCA非依赖的HRR缺陷肿瘤中使用PARP抑制剂。
- 野生型肿瘤中的潜在获益需结合合适治疗搭档并待前瞻性研究确认。
局限性
- 为系统综述与荟萃分析,结论受纳入研究异质性影响。
- 野生型肿瘤中的广泛疗效为探索性分析结果,需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Poly (ADP-ribose) polymerase-inhibitors (PARPis) showed antitumour activity in BRCA1/2-mutated cancers, with more heterogeneous outcomes in tumours harbouring mutations that impair other genes involved in the DNA homologous recombination repair (HRR) or wild-type (wt). METHODS: We conducted a systematic review and meta-analysis to better assess the role of PARPis in the treatment of metastatic solid tumours, with and without BRCA1/2 mutations. The primary end-point was progression-free survival (PFS). The secondary end-points were overall response rate (ORR) and overall survival (OS). A random-effects model was applied. RESULTS: Twenty-nine studies (8,839 patients) were included. PFS was significantly improved (hazard ratio [HR]: 0.59, 95% confidence interval [CI]: 0.51-0.68, p < 0.001), without being affected by BRCA mutational status (p = 0.65). Significant subgroup differences were observed with regard to the tumour site (p = 0.001), line of therapy (p = 0.002), control arm (p < 0.001), type of PARPi (p < 0.001) and trials' phase (p = 0.006). PARPis were associated with ORR (relative risk: 1.35, 95% CI: 1.16-1.56, p < 0.001), with significant subgroup differences observed with regard to treatment line (p = 0.03), control arm (p = 0.04) and PARPis (p < 0.001) and independent of mutational status (p = 0.44), tumour site (p = 0.86) and trials' phase (p = 0.09). OS was significantly improved by PARPis (HR: 0.86, 95% CI: 0.80-0.92, p < 0.001), regardless of mutational status (p = 0.57), tumour site (p = 0.82), treatment line (p = 0.22), control arm (p = 0.21), PARPis (p = 0.30) and trials' phase (p = 0.26). Finally, an exploratory subgroup analysis showed a significant PFS improvement (HR: 0.51, 95% CI: 0.43-0.60, p < 0.001) with PARPis in BRCA-wt/HRR-deficient tumours. CONCLUSION: Our results confirm the efficacy of already approved PARPi-based treatments in BRCA1/2-mutant solid tumours, support their role also in BRCA-independent HRR-deficient tumours and suggest a potentially broader efficacy in some wt tumours, perhaps with appropriate therapeutic partners. Prospective studies are warranted.
引用
- Schettini F, Giudici F, Bernocchi O, et al. Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis. Eur J Cancer. 2021. PMID: 33862496. doi:10.1016/j.ejca.2021.02.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。